NCT00709618 - Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

Neoplasms, Breast

Interventions

DRUG

Lapatinib, Vinorelbine

Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily

Trial Locations (22)

10065

GSK Investigational Site, New York

19106

GSK Investigational Site, Philadelphia

20817

GSK Investigational Site, Bethesda

21237

GSK Investigational Site, Baltimore

27403

GSK Investigational Site, Greensboro

30901

GSK Investigational Site, Augusta

32204

GSK Investigational Site, Jacksonville

33324

GSK Investigational Site, Plantation

35661

GSK Investigational Site, Muscle Shoals

38120

GSK Investigational Site, Memphis

39202

GSK Investigational Site, Jackson

43219

GSK Investigational Site, Columbus

52402

GSK Investigational Site, Cedar Rapids

63141

GSK Investigational Site, St Louis

64118

GSK Investigational Site, Kansas City

68114

GSK Investigational Site, Omaha

73120

GSK Investigational Site, Oklahoma City

74136

GSK Investigational Site, Tulsa

85715

GSK Investigational Site, Tucson

95817

GSK Investigational Site, Sacramento

97401

GSK Investigational Site, Eugene

97239-3098

GSK Investigational Site, Portland